Home Cart Sign in  
Chemical Structure| 2375815-63-5 Chemical Structure| 2375815-63-5

Structure of CD73-IN-3
CAS No.: 2375815-63-5

Chemical Structure| 2375815-63-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

LY-3475070 is a potent and selective CD73 Inhibitor with IC50 of 28 nM.

Synonyms: LY-3475070

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of CD73-IN-3

CAS No. :2375815-63-5
Formula : C15H18N4O2
M.W : 286.33
SMILES Code : C(C)(C)[C@@H]1[C@](C1)(C=2C=C(N=NC2C)C=3C(=O)NC(=O)NC3)[H]
Synonyms :
LY-3475070
MDL No. :MFCD01123336
InChI Key :WHRUIISQCORGKK-KOLCDFICSA-N
Pubchem ID :152262911

Safety of CD73-IN-3

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319
Precautionary Statements:P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313

Isoform Comparison

Biological Activity

Description
CD73-IN-3, derived from example 2 of patent WO2019168744 A1, is a potent inhibitor of CD73 (IC50=7.3 nM in Calu6 human cell assay). CD73-IN-3 shows promise for cancer research [1].

In Vitro:

Cell Line
Concentration Treated Time Description References
Bone marrow-derived macrophages (BMDMs) 1 μM 24 h To investigate the inhibitory effect of LY3475070 on CD73 expression in BMDMs and its impact on T cell function. Results showed that LY3475070 reversed the senescence-induced upregulation of CD73 in BMDMs and restored T cell proliferation and activity. PMC10845200

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice LLC subcutaneous tumor model Oral gavage 50 mg/kg Once daily for five days To evaluate the effect of LY3475070 on tumor growth and antitumor immunity in the senescent microenvironment. Results showed that LY3475070 significantly suppressed tumor growth and activated CD8+ T cell-mediated antitumor immunity. PMC10845200

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.49mL

0.70mL

0.35mL

17.46mL

3.49mL

1.75mL

34.92mL

6.98mL

3.49mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories